2025
Institutional
Investors'
Conference

Adimmune Corporation

TWSE: 4142

Disclaimer

- Adimmune has not released any financial forecast. Business and financial information presented in this brief and during the Q&A session, should they concern business operation or industrial development, may differ materially from actual results. These discrepancies are due to such risks and uncertainties as market demand changes, price fluctuations, competitive behavior, global economic conditions, exchange rate fluctuations, supply chains etc., which are beyond Adimmune's control.

- The forward-looking statements contained in this brief are based on Adimmune's current expectations and speak only as of the date hereof. Adimmune assumes no obligation to update forward-looking statements as the result of new information or future events or developments.

Agenda Overview

A.Company Profile

B.Business Outlook

C.Q&A

國際之光．免疫先鋒

國光生物科技股份有限公司

The only influenza vaccine manufacturer in Asia with both

EMA & US FDA GMP certifications

Established	**since 1965 (60-year experience in vaccines)**
Chairman	**Chi-Shean Chan, M.D.**
Employees	**524** (as of July 2025)
Total Area	**38,831 square meters**
Products	**Influenza Vaccine, Enterovirus 71 Vaccine, Tetanus Vaccine, Tuberculin**
Technology Partner	学校法人 北里研究所 THE KITASATO INSTITUTE
CDMO Service	SANOFI PASTEUR — Recombinant Protein Influenza Vaccine CDMO
	Techdow — Shenzhen Hepalink Group
	삼천당제약(주) — Korea's Sam Chun Dang Pharm. Co.,Ltd

Agenda Overview

A.Company Profile

B.Business Outlook

C.Q&A

CMO Client- S. MNC (from 2024)

New production line / Fill-finish Line 2; New product

New Project Introduction: From technology transfer to process validation batch production (~1 year; fee: USD 4–7 million)

1. 2024: New production line for recombinant protein influenza vaccine/ Commercial production in 2026 (May–July)
2. 2025: New protein-based vaccine/ Commercial production in 2027 (April, Sep–Oct)
3. 2026: Introduction of fully paper-based packaging/ Full commercial production in 2029

CMO-Asian Clients / Biosimilars

Sterile syringes with terminal sterilization for USA, Canada, and EU

- PFS F/F CDMO: launched in 2021
- Dedicated production line: Exclusive 2nd packaging line
- Terminal sterilization for pre-filled syringe (PFS) protein therapeutics
- Commercial production in 2025 (2nd packaging): EU, Canada, Asia

Enterovirus Vaccine
– Market Deployment

Country	Launch timeline	Partnership	Population aged 0~6	Demand: 2 doses/person	Births
Taiwan	Launched	-	1,433,014	2,866,029	134,856
Vietnam	2026 Q4	Vabiotech	10,405,361	20,810,721	1,387,961
Thailand	2027 Q1		5,067,952	10,135,904	462,240
Indonesia	2027 Q3	Etana	32,283,226	64,566,452	4,482,359
Macaw	2026 Q1	Cheng San Co., Ltd	51,763	103,525	3,607

Influenza Vaccine – Expansion to the Southern Hemisphere Market



CERTIFICADO DE BOAS PRATICAS Page 1 of 1

MINISTÉRIO DA SAÚDE
AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA

CERTIFICADO DE BOAS PRÁTICAS DE FABRICAÇÃO

A Agência Nacional de Vigilância Sanitária ANVISA no exercício de suas atribuições certifica que a empresa abaixo é periodicamente inspecionada e monitorada pelo Sistema Nacional de Vigilância Sanitária e que cumpre com as diretrizes de Boas Práticas de Fabricação dadas pela legislação brasileira, a qual está em consonância com as recomendações da Organização Mundial de Saúde.

ADIMMUNE CORPORATION

NO. 3, SEC. 1, TANXING RD., TANZI DIST., TAICHUNG CITY 42743, TAIWAN

TAICHUNG CITY - TAIWAN

CHINA, REPÚBLICA POPULAR

Linha(s) de Produção:

1) Produtos estéreis: Soluções Parenterais de Pequeno Volume com Preparação Asséptica

Valido até: 13/07/2022

Publicado no Diário Oficial da União por meio da Resolução - RE nº 2.397, na data de: 13/07/2020

Solicitado por: SANOFI MEDLEY FARMACÊUTICA LTDA., CNPJ: 10.588.556/0010-92

Documento emitido eletronicamente às: 16:40:29 do dia 14/07/2020 (Data/Hora de Brasília - DF)

Código de controle do comprovante: UAF2.QXAN.4HDB.GXSR.YWH2.7913.ITND.DVUR.93TN.52DQ

Verifique a autenticidade deste documento no endereço: http://www8.anvisa.gov.br/Peticionamento/validarcertificado8PF_BPDA/

https://www8.anvisa.gov.br/peticionamento/sat/FormularioCOTMF/CertificadoCerti4... 14/07/2020

- **2024:** Regulatory submission
- **2025:** PIC/S GMP inspection passed
- **2026:** Expected marketing authorization approval

Business Outlook

Adimmune's own products & CDMO

	2023	2024				2025				2026			
	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
QIV for South Hemisphere	Submission of marketing authorization & documentation review						On-site inspection (scheduled) & audit in Taiwan					Acquisition of marketing authorization & commercial production	
EV71 Vaccine-ASEAN										Submission of marketing authorization/ documentation review/on-site inspection			
CDMO: Recombinant Protein Vaccine DP (new demand)				Clarification of business terms & technical specifications		On-site inspection & audit in Taiwan			Acquisition of marketing authorization		Scaling commercial production		
CDMO: Ophthalmic Drug DP (Approved for Commercial Production)		On-site inspections for the North America/Europe/Northeast Asia markets & acquisition of marketing authorization					Annual commercial production for filling service						

* Enterovirus 71 vaccine is expected to obtained the marketing authorizations in ASEAN countries in 2027-2029.

Business Outlook (Strategic Development & New Product Co-Development)

- **Ongoing Expansion of Influenza Vaccine Market Overseas**
  - **Southern Hemisphere (Brazil)**
  - **Middle East & South Asia**
- **Strategic Partnerships – New Product Co-Development & Technology Transfer**
  - **Herpes Zoster Vaccine: Korea**
  - **Human Respiratory Syncytial Virus (RSV) and Influenza Bivalent Vaccine (Asia and Southern Hemisphere)**

Business Outlook
(New Capacity Deployment)

- **New Production Line (Automated Aseptic Filling Line)**
  - Annual capacity: Approx. 4 million doses
  - Expected commercial production launch: Q2 2026
- **Anticipated Business Impact**
  - Supports commercial-scale manufacturing of customized, small-batch, and high-value products
  - Enables clinical trial supply production, offering one-stop service from clinical to large-scale commercial manufacturing
  - Enhances the value of existing capacity and improves production scheduling flexibility

Business Growth: Phase II

Unit：NT$ 0.1 Billion

Phase I Globalization Expansion Strategy → **Phase II Acceleration** → **Phase II Growth**

Obtained the market authorization for influenza vaccine in China

Adimmune began its globalization strategy in 2015 with the acquisition of marketing authorization for its influenza vaccine in China. Since then, the company has achieved significant growth in both Adimmune's products and CDMO services, expanding its footprint from Taiwan to major global markets, including the U.S., Europe, China, Northeast Asia, Southeast Asia, Central Asia, and Eastern Europe.

By 2023, Adimmune successfully completed Phase I of its global expansion strategy. The strong performance of its partners in international markets has further solidified and strengthened these strategic partnerships.



As Adimmune moves into Phase II of its business growth, the company is building on the successful foundation established during Phase I of its global expansion and aims to drive further growth in its CDMO business, expand its own product portfolio into the southern hemisphere market, and introduce its bioreactor-derived Enterovirus 71 vaccine to the ASEAN region.

Q&A

THANK YOU

OFFICE

No. 3, Sec. 1, Tanxing Rd.,
Tanzi Dist., Taichung City
427003 , Taiwan (R.O.C.)

+886-4-25381220

https://www.adimmune.com.tw/en

TWSE: 4142